会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Method of making pure 3R-3'R stereoisomer of zeaxanthin for human
ingestion
    • 制备玉米黄质的纯3R-3'R立体异构体进行人体摄取的方法
    • US5854015A
    • 1998-12-29
    • US551166
    • 1995-10-31
    • Kevin M. GarnettDennis L. GierhartLuis H. Guerra-Santos
    • Kevin M. GarnettDennis L. GierhartLuis H. Guerra-Santos
    • A61K31/047C12P23/00
    • A61K31/047Y10S435/85
    • A method is disclosed for making the 3R-3'R stereoisomer of zeaxanthin as a sole detectable or heavily dominant (more than about 90%) stereoisomer, for human ingestion. Zeaxanthin, a yellowish pigment which is naturally present in macular cells in the center of the human retina, absorbs blue and near-ultraviolet light radiation, thereby protecting the retinal cells against phototoxic damage. Zeaxanthin preparations which contain only the desired R--R isomer can be produced by a strain of Flavobacterium multivorum cells (ATCC accession number 55238). These cells (and other cells transformed with their zeaxanthin-producing genes) do not create any detectable quantities of the undesired S--S or S-R isomers of zeaxanthin, and they do not synthesize significant quantities of other carotenoids which might compete against zeaxanthin for alimentary uptake after oral ingestion. After synthesis using cell fermentation, the zeaxanthin can be concentrated to about 5-20% by simple and inexpensive steps such as solvent extraction, and can be purified to much higher levels by other methods if desired. The isomerically pure preparations can be taken orally, either as a therapeutic drug by patients suffering from macular degeneration, or as a nutritional supplement by anyone who wants to reduce his or her risk of suffering from age-related macular degeneration, which is widespread among people over the age of about 50 or 60.
    • 公开了一种用于使玉米黄质的3R-3'R立体异构体作为唯一可检测或重占优势(超过约90%)立体异构体的方法,用于人体摄取。 天然存在于人类视网膜中心的黄斑细胞中的淡黄色素的玉米黄质吸收蓝色和近紫外光的辐射,从而保护视网膜细胞免受光毒性损伤。 仅含有所需R-R异构体的玉米黄质制剂可以通过多变黄杆菌细菌菌株(ATCC登录号55238)产生。 这些细胞(和其产生的玉米黄质的基因转化的其他细胞)不产生任何可检测量的玉米黄质的不希望的SS或SR异构体,并且它们不合成显着量的其它类胡萝卜素,其可以与口服玉米黄质竞争消化吸收 摄入 在使用细胞发酵合成后,可以通过简单且便宜的步骤如溶剂萃取将玉米黄质浓缩至约5-20%,并且如果需要可以通过其它方法纯化至更高的水平。 异构纯的制剂可以口服给药,作为患有黄斑变性的患者的治疗药物,或作为营养补充剂,任何人谁希望降低患有年龄相关性黄斑变性的风险,这在人群中很普遍 年龄约50或60岁。